Finerenone Slows eGFR Decline in Non-Diabetic CKD

FIND-CKD extends the kidney-protective role of finerenone from diabetic to non-diabetic chronic kidney disease, giving pharmacists a new evidence-based add-on to renin-angiotensin system blockade.

finerenonenonsteroidal mineralocorticoid receptor antagonistchronic kidney diseasenon-diabetic CKDalbuminuriahyperkalemiaeGFR slopeRAS inhibitorSGLT2 inhibitorrandomized controlled trialFIND-CKD Chronic Kidney Disease

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Jongs N, Smeijer JD, Brinker M, Rethemeier N, Schloemer P, Vesterinen P, Goldsbury D, Dizayee S, Mares JW, Perkovic V, FIND-CKD Investigators

Citation: Heerspink HJL, Neuen BL, Agarwal R, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. The New England journal of medicine. 2026. doi:10.1056/NEJMoa2604625

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →